Company research
Neuphoria Therapeutics Inc.
CIK 1191070Updated Nov 6, 2026
SecurityNEUP · NASDAQ · equity
Name history
BIONOMICS LIMITED/FI · through Dec 23, 2024
NEUP price & chart
Loading TradingView…
NASDAQ:NEUP on TradingView ↗About the company
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a public company incorporated in Delaware. Neuphoria is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing the lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor for the treatment of post-traumatic stress disorder (“PTSD”). BNC210 is a first-of-its-kind, well tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Following the announcement from the AFFIRM-1 Phase 3 clinical trial on October 20, 2025, in which Neuphoria announced that the trial missed its primary and secondary endpoints, Neuphoria has halted development of BNC210 in social anxiety disorder and is conducting a strategic review.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders
Items 1.01, 3.03, 9.01
DEFA14A filing
DEFA14A filing
DEF 14A filing
10-K filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 34,809,200Source | 30,713,319Source | — | 18,168,220Source | — | 22,917,207Source | — | 28,709,016Source | 28,589,614Source | 27,649,093Source | 43,003,902Source |
| Property, Plant and Equipment, NetUSD | — | 1,623Source | — | 1,683Source | — | 1,964Source | — | — | 2,771Source | 1,994Source | — |
| GoodwillUSD | 8,843,549Source | 8,451,038Source | 8,626,104Source | 8,407,271Source | 8,840,075Source | 8,903,988Source | 8,574,696Source | 3,498,222Source | 8,638,609Source | 8,690,018Source | 13,084,300Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,307,743Source | 4,970,474Source | — | 5,136,157Source | — | 5,301,839Source | — | 4,142,060Source | 4,804,791Source | 5,467,522Source | — |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 19,440,655Source | 17,044,750Source | 8,426,061Source | 4,344,578Source | 10,154,961Source | 8,082,410Source | 8,135,059Source | 19,865,531Source | 14,210,745Source | 12,608,109Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,605,340Source | 24,592Source | — | 35,561Source | — | 115,960Source | — | 813,431Source | 11,948Source | 126,884Source | — |
| Assets, CurrentUSD | 21,657,908Source | 17,090,239Source | — | 4,398,608Source | — | 8,429,478Source | — | 21,068,734Source | 15,040,831Source | 13,193,758Source | — |
| Operating Lease, Right-of-Use AssetUSD | — | 125,213Source | — | 150,519Source | — | 197,447Source | — | — | 102,612Source | 216,975Source | — |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 5,385,256Source | 4,716,011Source | — | 4,420,225Source | — | 5,846,843Source | — | 4,108,994Source | 9,587,040Source | 10,158,721Source | 9,856,043Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 54Source | 19Source | — | 16Source | — | — | — | 54Source | 19Source | — | — |
| Additional Paid in CapitalUSD | 218,385,436Source | 199,372,800Source | — | 198,189,833Source | — | 198,280,436Source | — | 218,461,772Source | 200,194,324Source | 198,481,038Source | — |
| Retained Earnings (Accumulated Deficit)USD | -186,894,178Source | -169,463,046Source | — | -180,725,207Source | — | -178,781,858Source | — | -191,798,634Source | -178,346,703Source | -177,977,071Source | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,067,368Source | -3,912,465Source | — | -3,716,647Source | — | -2,428,214Source | — | -2,063,170Source | -2,845,066Source | -3,013,595Source | — |
| Stockholders' Equity Attributable to ParentUSD | 29,423,944Source | 25,997,308Source | 17,945,737Source | 13,747,995Source | 19,497,443Source | 17,070,364Source | 17,227,512Source | 24,600,022Source | 19,002,574Source | 17,490,372Source | — |
| Liabilities and EquityUSD | 34,809,200Source | 30,713,319Source | — | 18,168,220Source | — | 22,917,207Source | — | 28,709,016Source | 28,589,614Source | 27,649,093Source | — |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 1,513,309Source | 1,552,063Source | — | 2,133,674Source | — | 2,551,713Source | — | 756,581Source | 4,220,760Source | 3,829,073Source | — |
| Operating Lease, Liability, CurrentUSD | — | 121,738Source | — | 118,492Source | — | 129,881Source | — | — | 116,314Source | 121,990Source | — |
| Accounts Payable, CurrentUSD | 627,185Source | 745,336Source | — | 1,530,667Source | — | 1,325,994Source | — | 385,584Source | 1,154,369Source | 2,243,662Source | — |
| Operating Lease, Liability, NoncurrentUSD | — | 19,322Source | — | 49,818Source | — | 89,469Source | — | — | — | 117,628Source | — |
| Deferred Income Tax Liabilities, NetUSD | 390,733Source | 761,737Source | — | 842,921Source | — | 831,324Source | — | 355,940Source | 495,113Source | 963,540Source | — |
| Other Liabilities, NoncurrentUSD | — | 3,647Source | — | 3,389Source | — | 3,437Source | — | — | — | 2,886Source | — |
| Additional Financial Items | |||||||||||
| AllowanceAccountForCreditLossesOfFinancialAssetsAUD | — | — | — | — | — | — | — | — | — | — | 0Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | 355,940Source | 495,113Source | — | 1,655,369Source |
| DeferredTaxLiabilityAssetAUD | — | — | — | — | — | — | — | — | — | — | -1,655,369Source |
| IntangibleAssetsOtherThanGoodwillAUD | — | — | — | — | — | — | — | — | — | — | 9,202,594Source |
| IssuedCapitalAUD | — | — | — | — | — | — | — | — | — | — | 223,412,662Source |
| TradeAndOtherCurrentPayablesAUD | — | — | — | — | — | — | — | — | — | — | 3,500,487Source |
| TradeAndOtherCurrentReceivablesAUD | — | — | — | — | — | — | — | — | — | — | 14,718Source |
| TradeAndOtherPayablesAUD | — | — | — | — | — | — | — | — | — | — | 3,500,487Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2025 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossAUD | — | — | — | — | — | — | — | — | — | — | — | -31,846,957Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 26,736Source | 351,600Source | 163,772Source | 814,808Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -10,924Source | 801,483Source | -114,936Source | -299,203Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | -917,668Source | -768,785Source | -917,663Source | 804,371Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -139,173Source | -468,427Source | -139,173Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | -4,433,063Source | -12,353,074Source | 77,229Source | -14,680,777Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | -227,338Source | 17,915,883Source | 1,528,276Source | 15,108,794Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | -4,522,034Source | 5,576,841Source | 1,601,755Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 19,440,655Source | 17,119,482Source | 8,503,792Source | 4,418,560Source | 8,164,901Source | 19,865,531Source | 14,288,690Source | 12,686,935Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 3,857Source | 17,433Source | 31,516Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 51,853Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | 138,367Source | 14,032Source | -3,750Source | 76,974Source | — |
| Additional Financial Items | ||||||||||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableAUD | — | — | — | — | — | — | — | — | — | — | — | 49,642Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableAUD | — | — | — | — | — | — | — | — | — | — | — | 714,207Source |
| AdjustmentsForSharebasedPaymentsAUD | — | — | — | — | — | — | — | — | — | — | — | 1,904,553Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | — | — | — | — | — | — | — | — | — | — | — | -33,555Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | 100,000Source | 500,000Source | 200,000Source | 100,000Source | — | — | 600,000Source | — |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,952,956Source | -748,018Source | 3,999,422Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | 435,193Source | -976,678Source | -637,467Source | 805,422Source | 2,874,694Source | 1,929,209Source | 239,686Source | 2,207,420Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | -233,044Source | -603,313Source | -242,348Source | 27,350Source | — |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -291,522Source | 172,946Source | 216,847Source | 629,501Source | -280,037Source | -535,722Source | -414,996Source | -209,842Source | — |
| General and Administrative ExpenseUSD | — | — | — | 1,687,403Source | 1,406,796Source | 1,195,485Source | 2,629,187Source | 1,666,824Source | 7,439,224Source | 7,773,442Source | 8,474,591Source | — |
| GoodwillUSD | — | — | — | 8,843,549Source | 8,451,038Source | 8,626,104Source | 8,407,271Source | 8,903,988Source | 3,498,222Source | 8,638,609Source | 8,690,018Source | 13,084,300Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 5,362,000Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | -34,793Source | -81,186Source | 16,383Source | 11,609Source | -132,187Source | -139,173Source | -468,366Source | -87,320Source | — |
| InterestPaidClassifiedAsOperatingActivitiesAUD | — | — | — | — | — | — | — | — | — | — | — | 29,230Source |
| InterestReceivedClassifiedAsOperatingActivitiesAUD | — | — | — | — | — | — | — | — | — | — | — | 479,726Source |
| Investment Income, InterestUSD | — | — | — | 186,171Source | 12,741Source | 52,615Source | 30,615Source | 36,096Source | 665,571Source | 166,498Source | 220,097Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -505,063Source | 11,262,161Source | -2,778,148Source | -1,943,349Source | -804,787Source | -13,451,931Source | -369,632Source | -15,492,166Source | — |
| Nonoperating Income (Expense)USD | — | — | — | 671,793Source | -796,218Source | -367,734Source | 1,771,771Source | 2,630,753Source | 2,859,962Source | 291,093Source | 2,312,890Source | — |
| Operating ExpensesUSD | — | — | — | 1,211,649Source | 3,022,807Source | 2,394,031Source | 4,366,226Source | 3,567,727Source | 17,625,231Source | 16,778,539Source | 17,892,376Source | — |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 47,608Source | — | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | — | — | — | — | — | — | — | — | — | — | — | 160,040Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 17,915,883Source | 1,528,276Source | — | — |
| ProceedsFromIssuingSharesAUD | — | — | — | — | — | — | — | — | — | — | — | 7,419,235Source |
| Restructuring CostsUSD | — | — | — | 42,414Source | — | — | — | — | 1,278,586Source | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2025 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 15,000,000Source | — | 662,715Source | — | 1,174,165Source | 15,649,448Source | — | 22,047Source |
| Operating Income (Loss)USD | — | — | — | -1,211,649Source | 11,977,193Source | -2,394,031Source | -3,703,511Source | -3,567,727Source | -16,451,066Source | -1,129,091Source | -17,892,376Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -539,856Source | 11,180,975Source | -2,761,765Source | -1,931,740Source | -936,974Source | -13,591,104Source | -837,998Source | -15,579,486Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | -34,793Source | -81,186Source | 16,383Source | 11,609Source | -132,187Source | -139,173Source | -468,366Source | -87,320Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -505,063Source | 11,262,161Source | -2,778,148Source | -1,943,349Source | -804,787Source | -13,451,931Source | -369,632Source | -15,492,166Source | — |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.09Source | 6.55Source | -2.83Source | -1.23Source | -0.62Source | -3.06Source | -0.23Source | -0.01Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.09Source | 6.55Source | -2.83Source | -1.79Source | -0.62Source | -3.06Source | -0.23Source | -0.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 5,411,244Source | 1,719,073Source | 981,040Source | 1,575,244Source | 1,300,065Source | 4,395,776Source | 1,622,924Source | 1,797,606,532Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 5,411,244Source | 1,719,073Source | 981,040Source | 1,575,244Source | 1,300,065Source | 4,395,776Source | 1,622,924Source | 1,797,606,532Source | — |
| Additional Financial Items | ||||||||||||
| AdministrativeExpenseAUD | — | — | — | — | — | — | — | — | — | — | — | 8,636,180Source |
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | — | — | — | 0.25Source |
| BasicEarningsLossPerShareAUD/shares | — | — | — | — | — | — | — | — | — | — | — | -0.02Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 61Source | 51,853Source | — |
| DeferredTaxExpenseIncomeAUD | — | — | — | — | — | — | — | — | — | — | — | -206,792Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | — | — | — | — | — | — | — | — | — | — | — | -206,792Source |
| DepreciationAndAmortisationExpenseAUD | — | — | — | — | — | — | — | — | — | — | — | 1,156,992Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | 165,713Source | 662,955Source | 662,890Source | 662,991Source | — |
| DepreciationRightofuseAssetsAUD | — | — | — | — | — | — | — | — | — | — | — | 170,900Source |
| DilutedEarningsLossPerShareAUD/shares | — | — | — | — | — | — | — | — | — | — | — | -0.02Source |
| EmployeeBenefitsExpenseAUD | — | — | — | — | — | — | — | — | — | — | — | 5,866,810Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | 435,193Source | -976,678Source | -637,467Source | 805,422Source | 2,874,694Source | 1,929,209Source | 239,686Source | 2,207,420Source | — |
| FinanceCostsAUD | — | — | — | — | — | — | — | — | — | — | — | 29,230Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | -233,044Source | -603,313Source | -242,348Source | 27,350Source | — |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -291,522Source | 172,946Source | 216,847Source | 629,501Source | -280,037Source | -535,722Source | -414,996Source | -209,842Source | — |
| General and Administrative ExpenseUSD | — | — | — | 1,687,403Source | 1,406,796Source | 1,195,485Source | 2,629,187Source | 1,666,824Source | 7,439,224Source | 7,773,442Source | 8,474,591Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 5,362,000Source | 0Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -8,254,064Source | -7,111,507Source | -1,819,496Source | — |
| IncomeTaxExpenseContinuingOperationsAUD | — | — | — | — | — | — | — | — | — | — | — | -206,792Source |
| InterestExpenseOnLeaseLiabilitiesAUD | — | — | — | — | — | — | — | — | — | — | — | 21,278Source |
| Investment Income, InterestUSD | — | — | — | 186,171Source | 12,741Source | 52,615Source | 30,615Source | 36,096Source | 665,571Source | 166,498Source | 220,097Source | — |
| Nonoperating Income (Expense)USD | — | — | — | 671,793Source | -796,218Source | -367,734Source | 1,771,771Source | 2,630,753Source | 2,859,962Source | 291,093Source | 2,312,890Source | — |
| Operating ExpensesUSD | — | — | — | 1,211,649Source | 3,022,807Source | 2,394,031Source | 4,366,226Source | 3,567,727Source | 17,625,231Source | 16,778,539Source | 17,892,376Source | — |
| Other General and Administrative ExpenseUSD | — | — | — | — | 15,921Source | 16,945Source | 16,700Source | 16,121Source | 36,536Source | 50,859Source | 68,296Source | — |
| OtherIncomeAUD | — | — | — | — | — | — | — | — | — | — | — | 627,558Source |
| OtherOperatingIncomeExpenseAUD | — | — | — | — | — | — | — | — | — | — | — | 627,558Source |
| ProfitLossBeforeTaxAUD | — | — | — | — | — | — | — | — | — | — | — | -32,053,749Source |
| Research and Development ExpenseUSD | — | — | — | — | 1,616,011Source | 1,198,546Source | 1,737,039Source | 1,900,903Source | — | 9,005,097Source | 9,417,785Source | 19,613,270Source |
| Restructuring CostsUSD | — | — | — | 42,414Source | — | — | — | — | 1,278,586Source | — | — | — |
| RevenueAUD | — | — | — | — | — | — | — | — | — | — | — | 22,047Source |
| RevenueFromInterestAUD | — | — | — | — | — | — | — | — | — | — | — | 479,726Source |
Filing attachments
ea030914601ex4-2.htm · 8-K · 2026-10-23
Exhibit 4.2 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This Amendment No. 1, dated as of October 23, 2026 (this “ Amendment ”), amends that certain Rights Agreement, dated as of October 27, 2025 (the “ Rights Agreement ”), by and between Neuphoria Therapeutics Inc., a Delaware corporation (the “ Company ”), and Computershare Trust Company, N.A. (the “ Rights Agent ”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Rights Agreement. WHERE…
Read attachment ↗ea029891401ex99-1.htm · DEFA14A · 2026-07-24
Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF EU REGULATION NO. 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing All-share transaction creating a combined company to operate as Scance…
Read attachment ↗ea029891401ex99-2.htm · DEFA14A · 2026-07-24
Exhibit 99.2 Corporate Presentation July 2026 Active Immunotherapy Ready For Prime Time 2 Disclaimer This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate", "continue" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwa…
Read attachment ↗ea029891401ex99-1.htm · 8-K · 2026-07-24
EX-99.1 10 ea029891401ex99-1.htm PRESS RELEASE, DATED AS OF JULY 23, 2026 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF EU REGULATION NO. 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financi…
Read attachment ↗ea029891401ex99-2.htm · 8-K · 2026-07-24
EX-99.2 11 ea029891401ex99-2.htm INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026 Exhibit 99.2 Corporate Presentation July 2026 Active Immunotherapy Ready For Prime Time 2 Disclaimer This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate", "continue" and similar expressions (as well as …
Read attachment ↗ea026256101ex4-1_neuphoria.htm · 8-K · 2025-10-27
EX-4.1 3 ea026256101ex4-1_neuphoria.htm RIGHTS AGREEMENT, DATED AS OF OCTOBER 27, 2025 BETWEEN NEUPHORIA THERAPEUTICS INC. AND COMPUTERSHARE TRUST COMPANY, N.A., WHICH INCLUDES THE FORM OF CERTIFICATE OF DESIGNATION AS EXHIBIT A, THE FORM OF RIGHT CERTIFICATE AS EXHIBIT B Exhibit 4.1 RIGHTS AGREEMENT October 27, 2025 TABLE OF CONTENTS Page SECTIO…
Read attachment ↗